HK Stock Market Move | HUA MEDICINE-B(02552) rose nearly 10% in intraday trading. Its core product, Hualing Tablets, was recently approved for listing in Hong Kong.
China Lead Pharmaceuticals-B (02552) rose nearly 10% during trading, as of the time of writing, it has risen by 6.69% to HK$3.03, with a trading volume of HK$10.61 million.
HUA MEDICINE-B(02552) rose nearly 10% during the trading session, closing with a 6.69% increase at HK$3.03, with a turnover of HK$10.61 million.
On the news front, on March 3rd, Hua Medicine announced that its globally innovative drug, the Glucokinase Activator (GKA) dorzagliatin (brand name: MYHOMSIS, Hua Ling Tablets), has been approved for listing by the Hong Kong Department of Health for the treatment of adult type 2 diabetes. This milestone signifies that Hua Medicine, with Hong Kong as the hub, has taken a critical step towards its strategic layout to enter the Southeast Asian and global markets from China.
Related Articles
JD INDUSTRIALS (07618) announced its annual performance, with a net profit of 2.314 billion yuan, an increase of 203.8% year-on-year.
HUNLICAR GROUP (03638) spent HK$57,000 on March 5 to repurchase 5,000 shares.
RSUN PPT (01996) accumulated contract sales amount in the first two months decreased by 78.87% year-on-year to RMB 2.35 billion.
JD INDUSTRIALS (07618) announced its annual performance, with a net profit of 2.314 billion yuan, an increase of 203.8% year-on-year.
HUNLICAR GROUP (03638) spent HK$57,000 on March 5 to repurchase 5,000 shares.
RSUN PPT (01996) accumulated contract sales amount in the first two months decreased by 78.87% year-on-year to RMB 2.35 billion.
RECOMMEND
